SER-109 + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Clostridium Difficile Infection

Conditions

Clostridium Difficile Infection

Trial Timeline

Jul 10, 2017 → Sep 29, 2020

NCT ID

NCT03183128

About SER-109 + Placebo

SER-109 + Placebo is a phase 3 stage product being developed by Seres Therapeutics for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03183128. Target conditions include Clostridium Difficile Infection.

What happened to similar drugs?

9 of 20 similar drugs in Clostridium Difficile Infection were approved

Approved (9) Terminated (5) Active (11)

✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved

✅Fidaxomicin + VancomycinAstellas PharmaApproved

✅Fidaxomicin + VancomycinMerckApproved

✅Vancomycin + FidaxomicinMerckApproved

✅bezlotoxumab + Vancomycin OralMerckApproved

✅Fidaxomicin 200 mg + Placebo + VancomycinMerckApproved

✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03183128	Phase 3	Completed	Jul 10, 2017	Sep 29, 2020	Clostridium Difficile Infection
NCT02437487	Phase 2	Completed	May 1, 2015	Oct 1, 2016	Clostridium Difficile

Competing Products

20 competing products in Clostridium Difficile Infection

See all competitors

Product	Company	Stage	Hype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2	Dr. Reddy's Laboratories	Phase 2	32
Fidaxomicin + Vancomycin + Placebo	Astellas Pharma	Approved	35
Fidaxomicin + Treatment for CDI other than fidaxomicin Type	Astellas Pharma	Pre-clinical	26
OPT-80 + vancomycin	Astellas Pharma	Phase 3	40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules	Astellas Pharma	Phase 3	40
Fidaxomicin + Vancomycin	Astellas Pharma	Approved	43
Fidaxomicin + Vancomycin	Merck	Approved	43
fidaxomicin + Placebo	Merck	Phase 3	40
Surotomycin + Placebo	Merck	Phase 1	29
CB-183,315 + Placebo + Vancomycin	Merck	Phase 2	35
Surotomycin + Placebo	Merck	Phase 1	29
MK-6072 + MK-3415A + Placebo + SOC	Merck	Phase 3	40
Vancomycin + Fidaxomicin	Merck	Approved	43
Fidaxomicin	Merck	Pre-clinical	18
Bezlotoxumab + Standard CDI treatment	Merck	Pre-clinical	26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOC	Merck	Phase 3	40
Fidaxomicin + Vancomycin + Matching Placebo to Fidaxomicin	Merck	Phase 3	40
bezlotoxumab + Vancomycin Oral	Merck	Approved	43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)	Merck	Phase 3	40
Bezlotoxumab Injection [Zinplava]	Merck	Pre-clinical	26